Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis

2019-11-12 18:25:18 | BioPortfolio


Patients with peritoneal metastasis of colorectal or high grade appendiceal origin who are candidates for cytoreductive surgery with HIPEC (hyperthermic intraperitoneal chemotherapy) will be enrolled in this study. Blood collection for measurements of plasma cell-free DNA hydroxymethylation signatures will be performed at different time points, before and after surgery, in order to determine if plasma hydroxymethylation signatures are more sensitive than conventional tumor markers in identifying clinically detectable recurrence at 1 year after surgery.


This will be a prospective single arm biomarker (plasma-free DNA 5-hydroxymethylation) study. Fifty-five Adult patients with peritoneal metastases of colorectal and appendiceal origin who are candidates for a curative surgery and fulfill the inclusion criteria will be offered to participate in this study. In addition to the postoperative standard of care oncological surveillance of these patients which includes periodic physical examinations, cross sectional imaging studies (CT or MRI) and blood work for conventional tumor markers, serial measurements of plasma hydroxymethylation signatures will be performed. We will use a model developed in a separate pilot study to identify recurrent peritoneal metastasis based on 5hmC signatures. As part of this study, blood collection for measurements of plasma hydroxymethylation signatures of target genes will be performed at seven time points:

- Just before surgery (During the preoperative clinic visit or at the operating room).

- 5-7 days after surgery (just before hospital discharge).

- 6 weeks after surgery (first postoperative clinic visit).

- 3 months after surgery (second postoperative clinic visit).

- 6 months after surgery (third postoperative clinic visit).

- 9 months after surgery (fourth postoperative clinic visit).

- 12 months after surgery (fifth postoperative clinic visit). Standard of care surveillance elements that include patient history and physical examination, conventional blood biomarkers (CEA, CA 19-9 and CA 125) and cross sectional imaging of the chest, abdomen and pelvis will be undertaken simultaneously at similar time points. We will then compare the sensitivities of DNA hydroxymethylation signatures and conventional blood biomarkers in diagnosing clinically detectable recurrence at 1 year after surgery. We hypothesize that plasma hydroxymethylation signatures have higher sensitivity in identifying clinically detectable recurrence when compared with conventional tumor markers (CEA, CA 19-9 and CA 125).

Study Design


Colorectal Cancer Stage IV


prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study


The University of Chicago
United States




University of Chicago

Results (where available)

View Results


Published on BioPortfolio: 2019-11-12T18:25:18-0500

Clinical Trials [4177 Associated Clinical Trials listed on BioPortfolio]

Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis

Prospective evaluation of the circulating cell-free DNA-based epigenetic biomarker (mSEPT9) through a cross-sectional biomarker phase II design. The aim of the SEPT9-CROSS study is to asse...

Comparison of KRAS/BRAF Mutational Status With Conventional Techniques and Plasma Samples Analysis

The goal of this multicenter prospective study is to validate, and ultimately translate in routine clinical practice, the use of plasma analysis of ccfDNA for the determination of KRAS mut...

Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke

The purpose of the research is to use plasma free fatty acid profiling as a biomarker for ischemic stroke. The plasma free acid profile will be specifically and significantly changed in ea...

Early Diagnosis of Oral Cancer by Detectiong p16 Hydroxymethylation

The purpose of this study is to verify the function of p16 hydroxymethylation diagnostic reagents in early diagnosis of oral cancer.

DNA Methylation and Hydroxymethylation Levels in Patients With Coronary Heart Disease

The purpose of this trial is to investigate the relationship between DNA methylation and hydroxymethylation and the expression of DNMTs, TET family gen and coronary heart disease.

PubMed Articles [44611 Associated PubMed Articles listed on BioPortfolio]

Comprehensive Evaluation of the Factors Affecting Plasma Circulating Cell-Free DNA Levels and Their Application in Diagnosing Nonsmall Cell Lung Cancer.

Circulating cell-free DNA (ccfDNA) is a valuable biomarker, but the ccfDNA levels are influenced by variations that occur during sample processing. The feasibility of using ccfDNA as a diagnostic biom...

Plasma total-tau as a biomarker of stroke risk in the community.

Higher plasma total-tau level is associated with incident dementia but its relationship with stroke risk is unknown. In this prospective community-based study, we evaluated plasma total-tau level as a...

Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.

Tumor mutational burden is an emerging biomarker of response to immune checkpoint inhibitors (ICI), whose clinical adoption is challenging. We hypothesized that targeting limited but relevant genetic ...

Plasma miR-30a-5p as an early novel noninvasive diagnostic and prognostic biomarker for lung cancer.

Circulation miRNAs have become increasingly appreciated in the diagnosis and prognosis of lung cancer. This study aims to identify and evaluate plasma miRNA-30a-5p as an early noninvasive biomarker fo...

Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma.

Recent literature has demonstrated the potential of "liquid biopsy" and detection of circulating, cell-free tumor deoxyribonucleic acid (ctDNA) as a cancer biomarker. However, to date there is a lack ...

Medical and Biotech [MESH] Definitions

Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.

A fractionated cell extract that maintains a biological function. A subcellular fraction isolated by ultracentrifugation or other separation techniques must first be isolated so that a process can be studied free from all of the complex side reactions that occur in a cell. The cell-free system is therefore widely used in cell biology. (From Alberts et al., Molecular Biology of the Cell, 2d ed, p166)

Ionized gases, consisting of free electrons and ionized atoms or molecules which collectively behave differently than gas, solid, or liquid. Plasma gases are used in biomedical fields in surface modification; biological decontamination; dentistry (e.g., PLASMA ARC DENTAL CURING LIGHTS); and in other treatments (e.g., ARGON PLASMA COAGULATION).

MicroRNAs found in cell-free BODY FLUIDS such as SERUM; PLASMA; SALIVA; OR URINE.

The commission charged with evaluating issues and factors which affect the implementation of the PROSPECTIVE PAYMENT SYSTEM.

More From BioPortfolio on "Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis"

Quick Search

Relevant Topics

Surgical treatments
Surgery is a technology consisting of a physical intervention on tissues. All forms of surgery are considered invasive procedures; so-called "noninvasive surgery" usually refers to an excision that does not penetrate the structure being exci...

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Searches Linking to this Trial